ZA200007653B - Characterisation of gene function using double stranded RNA inhibition. - Google Patents
Characterisation of gene function using double stranded RNA inhibition. Download PDFInfo
- Publication number
- ZA200007653B ZA200007653B ZA200007653A ZA200007653A ZA200007653B ZA 200007653 B ZA200007653 B ZA 200007653B ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 B ZA200007653 B ZA 200007653B
- Authority
- ZA
- South Africa
- Prior art keywords
- dna
- promoter
- transcription factor
- organism
- vector
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 120
- 108090000623 proteins and genes Proteins 0.000 title claims description 115
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims description 78
- 230000005764 inhibitory process Effects 0.000 title description 8
- 238000012512 characterization method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 129
- 239000013598 vector Substances 0.000 claims description 128
- 108020004414 DNA Proteins 0.000 claims description 117
- 108091023040 Transcription factor Proteins 0.000 claims description 75
- 102000040945 Transcription factor Human genes 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 63
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 52
- 239000013612 plasmid Substances 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 49
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 238000013518 transcription Methods 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 230000035897 transcription Effects 0.000 claims description 42
- 230000009261 transgenic effect Effects 0.000 claims description 41
- 241000588724 Escherichia coli Species 0.000 claims description 37
- 238000010367 cloning Methods 0.000 claims description 24
- 241000244206 Nematoda Species 0.000 claims description 22
- 238000002474 experimental method Methods 0.000 claims description 21
- 230000000977 initiatory effect Effects 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 238000001086 yeast two-hybrid system Methods 0.000 claims description 18
- 230000010354 integration Effects 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 14
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 13
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 230000033228 biological regulation Effects 0.000 claims description 10
- 241000607479 Yersinia pestis Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 101150015886 nuc-1 gene Proteins 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 101150110777 let-858 gene Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 101100459320 Caenorhabditis elegans myo-2 gene Proteins 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 5
- 108700008625 Reporter Genes Proteins 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 206010061217 Infestation Diseases 0.000 claims description 4
- 101150117157 MYO3 gene Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 238000010396 two-hybrid screening Methods 0.000 claims description 3
- 241000380490 Anguina Species 0.000 claims description 2
- 241000294569 Aphelenchoides Species 0.000 claims description 2
- 241000580217 Belonolaimus Species 0.000 claims description 2
- 241000243770 Bursaphelenchus Species 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 241000399934 Ditylenchus Species 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 241001442498 Globodera Species 0.000 claims description 2
- 241001480224 Heterodera Species 0.000 claims description 2
- 241001540513 Hoplolaimus Species 0.000 claims description 2
- 241001220360 Longidorus Species 0.000 claims description 2
- 241001143352 Meloidogyne Species 0.000 claims description 2
- 241000201433 Nacobbus Species 0.000 claims description 2
- 241001220391 Paratrichodorus Species 0.000 claims description 2
- 241000193943 Pratylenchus Species 0.000 claims description 2
- 241000201377 Radopholus Species 0.000 claims description 2
- 241001540480 Rotylenchulus Species 0.000 claims description 2
- 241001220308 Trichodorus Species 0.000 claims description 2
- 241001267618 Tylenchulus Species 0.000 claims description 2
- 101150033660 UL6 gene Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 description 24
- 230000009368 gene silencing by RNA Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 238000010276 construction Methods 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 238000011176 pooling Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 3
- 101100048437 Caenorhabditis elegans unc-22 gene Proteins 0.000 description 3
- 101100243717 Cochliobolus carbonum PGN1 gene Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101150066002 GFP gene Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 101100016388 Arabidopsis thaliana PAS2 gene Proteins 0.000 description 2
- 101100011366 Caenorhabditis elegans egl-15 gene Proteins 0.000 description 2
- 101100071585 Caenorhabditis elegans hsp-16.2 gene Proteins 0.000 description 2
- 101100074836 Caenorhabditis elegans lin-22 gene Proteins 0.000 description 2
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101100297150 Komagataella pastoris PEX3 gene Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101100315760 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX4 gene Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 101150086731 ges-1 gene Proteins 0.000 description 2
- 230000010196 hermaphroditism Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150114748 unc-119 gene Proteins 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101100064098 Caenorhabditis elegans dpy-7 gene Proteins 0.000 description 1
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 101150046414 ce gene Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 101150034492 gdhA-2 gene Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10241—Use of virus, viral particle or viral elements as a vector
- C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Catching Or Destruction (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9814536.0A GB9814536D0 (en) | 1998-07-03 | 1998-07-03 | Characterisation of gene function using double stranded rna inhibition |
| GBGB9827152.1A GB9827152D0 (en) | 1998-07-03 | 1998-12-09 | Characterisation of gene function using double stranded rna inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200007653B true ZA200007653B (en) | 2002-09-19 |
Family
ID=26313977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200007653A ZA200007653B (en) | 1998-07-03 | 2000-12-19 | Characterisation of gene function using double stranded RNA inhibition. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20030061626A1 (is) |
| EP (5) | EP1093526A2 (is) |
| JP (3) | JP4353639B2 (is) |
| KR (4) | KR20040066200A (is) |
| CN (3) | CN1900319A (is) |
| AT (2) | ATE419383T1 (is) |
| AU (1) | AU769223B2 (is) |
| BR (1) | BR9911802A (is) |
| CA (2) | CA2332619C (is) |
| CY (2) | CY1108920T1 (is) |
| CZ (2) | CZ304897B6 (is) |
| DE (5) | DE69940219D1 (is) |
| DK (2) | DK1484415T3 (is) |
| ES (2) | ES2327334T3 (is) |
| GB (4) | GB9827152D0 (is) |
| HK (1) | HK1029142A1 (is) |
| HU (1) | HU230602B1 (is) |
| IL (3) | IL140467A0 (is) |
| IN (2) | IN2001DE00006A (is) |
| IS (1) | IS2816B (is) |
| MX (1) | MX234065B (is) |
| NO (1) | NO327729B1 (is) |
| NZ (1) | NZ509182A (is) |
| PL (3) | PL216779B1 (is) |
| PT (2) | PT1197567E (is) |
| RU (1) | RU2240349C2 (is) |
| WO (1) | WO2000001846A2 (is) |
| ZA (1) | ZA200007653B (is) |
Families Citing this family (253)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| DK1624060T3 (da) | 1998-03-20 | 2012-04-10 | Commw Scient Ind Res Org | Kontrol af genekspression |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| WO2000044914A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
| US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| CN1375004A (zh) * | 1999-04-21 | 2002-10-16 | 惠氏公司 | 抑制多核苷酸序列的功能的方法和组合物 |
| US6924109B2 (en) * | 1999-07-30 | 2005-08-02 | Agy Therapeutics, Inc. | High-throughput transcriptome and functional validation analysis |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| GB9930691D0 (en) * | 1999-12-24 | 2000-02-16 | Devgen Nv | Improvements relating to double-stranded RNA inhibition |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| NZ553687A (en) | 2000-03-30 | 2010-03-26 | Whitehead Biomedical Inst | RNA sequence-specific mediators of RNA interference |
| GB0012229D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Lipid uptake assays |
| GB0012233D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
| GB2362383B (en) * | 2000-05-19 | 2003-12-31 | Devgen Nv | Gene expression system |
| US7083947B2 (en) | 2000-05-19 | 2006-08-01 | Devgen Nv | Assay techniques using nematode worms |
| AU2001275474A1 (en) * | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| NZ527719A (en) * | 2001-01-25 | 2006-12-22 | Virxsys Corp | Methods and compositions for identifying gene function |
| WO2002059294A1 (en) | 2001-01-26 | 2002-08-01 | Commonwealth Scientific And Industrial Research O Rganisation | Methods and means for producing efficient silencing construct using recombinational cloning |
| US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| US20040110177A1 (en) * | 2001-02-02 | 2004-06-10 | Axel Ullrich | Method for identifying functional nucleic acids |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| WO2003070887A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070884A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2415486B1 (en) | 2001-05-18 | 2017-02-22 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2003070972A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CA2453183C (en) | 2001-07-12 | 2016-05-10 | University Of Massachusetts | In vivo production of small interfering rnas that mediate gene silencing |
| US7612194B2 (en) * | 2001-07-24 | 2009-11-03 | Monsanto Technology Llc | Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof |
| CA2458842C (en) | 2001-08-31 | 2011-01-25 | Riken | Plant system for comprehensive gene function analysis with the use of full-length cdnas |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| US20030150017A1 (en) * | 2001-11-07 | 2003-08-07 | Mesa Jose Ramon Botella | Method for facilitating pathogen resistance |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| JP2005515780A (ja) | 2002-02-01 | 2005-06-02 | セクイター インコーポレイテッド | 二本鎖オリゴヌクレオチド |
| AU2003211058A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003213057A1 (en) * | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incoporated | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003228667A1 (en) * | 2002-04-22 | 2003-12-19 | Sirna Therapeutics Inc. | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
| US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| WO2003095652A2 (de) * | 2002-05-08 | 2003-11-20 | Xantos Biomedicine Ag | EXPRESSIONSKONSTRUKTE ZUR HERSTELLUNG VON DOPPELSTRANG (ds) RNA UND DEREN ANWENDUNG |
| WO2003100094A2 (en) * | 2002-05-23 | 2003-12-04 | Devgen Nv | Method for determining the influence of a compound on cholesterol transport |
| US20100009856A1 (en) * | 2002-06-21 | 2010-01-14 | Sinogenomax Sompany LTD. | Randomized dna libraries and double-stranded rna libraries, use and method of production thereof |
| BR0312580A (pt) * | 2002-07-10 | 2006-10-10 | Univ Kansas State | composições e métodos para controlar nematódeos parasitas |
| US7655790B2 (en) | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| SI1857547T1 (en) | 2002-08-05 | 2018-05-31 | Silence Therapeutics Gmbh | FURTHER NEW MODELS OF THE INTERFERENCE RNA MOLECULAR |
| US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
| AU2003264727A1 (en) * | 2002-09-04 | 2004-03-29 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003298733B2 (en) | 2002-11-27 | 2009-06-18 | Agena Bioscience, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| AU2003296696A1 (en) * | 2002-12-23 | 2004-07-14 | Devgen Nv | Kinase sequences |
| EP1622572B1 (en) | 2003-04-30 | 2017-12-20 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| IL155783A (en) | 2003-05-05 | 2010-11-30 | Technion Res & Dev Foundation | Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use |
| ATE516047T1 (de) | 2003-05-09 | 2011-07-15 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und anwendungsverfahren |
| US20070092910A1 (en) * | 2003-06-17 | 2007-04-26 | Devgen Nv | Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
| WO2005024068A2 (en) | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| US20060272049A1 (en) * | 2003-11-17 | 2006-11-30 | Waterhouse Peter M | Insect resistance using inhibition of gene expression |
| US7700280B2 (en) | 2003-12-31 | 2010-04-20 | The Penn State Research Foundation | Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer |
| US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
| WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
| US7622301B2 (en) * | 2004-02-24 | 2009-11-24 | Basf Plant Science Gmbh | Compositions and methods using RNA interference for control of nematodes |
| US7608394B2 (en) * | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| EP2395098B1 (en) | 2004-03-26 | 2015-07-15 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| JP5223072B2 (ja) | 2004-04-02 | 2013-06-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物 |
| EP1818405B1 (en) | 2004-04-09 | 2015-06-03 | Monsanto Technology, LLC | Compositions and methods for control of insect infestations in plants |
| CA2557532A1 (en) | 2004-04-23 | 2005-11-10 | Angela M. Christiano | Inhibition of hairless protein mrna |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| WO2006009575A1 (en) | 2004-06-22 | 2006-01-26 | The Board Of Trustees Of The University Of Illinois | METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA |
| US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
| WO2007001324A2 (en) | 2004-07-23 | 2007-01-04 | The University Of North Carolina At Chapel Hill | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
| ATE518954T1 (de) | 2004-08-18 | 2011-08-15 | Lorus Therapeutics Inc | Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen |
| CA2940718C (en) | 2004-09-24 | 2019-06-18 | J.R. Simplot Company | Gene silencing |
| US20060247197A1 (en) | 2004-10-04 | 2006-11-02 | Van De Craen Marc | Method for down-regulating gene expression in fungi |
| EP1799029B1 (en) | 2004-10-13 | 2012-05-16 | University Of Georgia Research Foundation, Inc. | Nematode resistant transgenic plants |
| AU2005299492B2 (en) | 2004-10-21 | 2011-09-01 | Venganza, Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
| US8772254B2 (en) | 2004-10-25 | 2014-07-08 | Devgen N.V. | Method and constructs for delivering double stranded RNA to pest organisms |
| CA2582550C (en) | 2004-10-25 | 2019-06-25 | Devgen Nv | Rna constructs |
| JP2008526883A (ja) | 2005-01-07 | 2008-07-24 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| US8519225B2 (en) | 2006-02-10 | 2013-08-27 | Monsanto Technology Llc | Identification and use of target genes for control of plant parasitic nematodes |
| US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
| WO2006105361A2 (en) | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| EP1888052A2 (en) | 2005-05-12 | 2008-02-20 | Wisconsin Alumni Research Foundation | Blockade of pin1 prevents cytokine production by activated immune cells |
| WO2006129204A2 (en) * | 2005-05-31 | 2006-12-07 | Devgen Nv | Rnai for control of insects and arachnids |
| WO2007011702A2 (en) | 2005-07-15 | 2007-01-25 | The University Of North Carolina At Chapel Hill | Use of egfr inhibitors to prevent or treat obesity |
| JP5530632B2 (ja) | 2005-09-16 | 2014-06-25 | デブジェン エヌブイ | ＲＮＡｉを使用した害虫の抑制方法 |
| ES2545093T3 (es) | 2005-09-16 | 2015-09-08 | Devgen N.V. | Métodos basados en plantas transgénicas para plagas de plantas usando ARNi |
| AU2006292362B2 (en) | 2005-09-16 | 2013-02-14 | Monsanto Technology Llc | Methods for genetic control of insect infestations in plants and compositions thereof |
| CN101268194A (zh) | 2005-09-20 | 2008-09-17 | 巴斯福植物科学有限公司 | 使用ta-siRNA调控基因表达的方法 |
| US9286469B2 (en) * | 2005-12-16 | 2016-03-15 | Cisco Technology, Inc. | Methods and apparatus providing computer and network security utilizing probabilistic signature generation |
| BRPI0706368A2 (pt) | 2006-01-06 | 2011-03-22 | Univ Georgia | composição, vetor, método para fornecer resistência ao cisto nematódeo a uma planta, proteìna de fusão, método para inibir atividade biológica, ácido nucléico isolado |
| JP5474355B2 (ja) | 2006-01-12 | 2014-04-16 | デブジェン エヌブイ | ＲＮＡｉを利用する植物害虫のための遺伝子組換え植物系方法 |
| US8906876B2 (en) | 2006-01-12 | 2014-12-09 | Devgen Nv | Methods for controlling pests using RNAi |
| JP5474356B2 (ja) | 2006-01-12 | 2014-04-16 | デブジェン エヌブイ | ＲＮＡｉを使用する害虫を制御する方法 |
| US20080022423A1 (en) * | 2006-02-03 | 2008-01-24 | Monsanto Technology Llc | IN PLANTA RNAi CONTROL OF FUNGI |
| CA2836368C (en) * | 2006-02-13 | 2020-04-07 | Monsanto Technology Llc | Method for managing crop pest resistance |
| US20100068172A1 (en) * | 2006-03-16 | 2010-03-18 | Devgen N.V. | Nematode Control |
| WO2007123777A2 (en) | 2006-03-30 | 2007-11-01 | Duke University | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
| PL216037B1 (pl) * | 2006-06-09 | 2014-02-28 | Inst Biotechnologii I Antybiotykow | Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu |
| AU2007314477B2 (en) | 2006-07-11 | 2012-03-29 | Rutgers, The State University Of New Jersey | MG53 compositions and methods of use |
| WO2008014426A2 (en) | 2006-07-28 | 2008-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| EP2104513B1 (en) | 2006-11-27 | 2015-05-20 | diaDexus, Inc. | Ovr110 antibody compositions and methods of use |
| CN101195821A (zh) * | 2006-12-04 | 2008-06-11 | 中国科学院上海生命科学研究院 | 利用RNAi技术改良植物抗虫性的方法 |
| EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| CN101641010A (zh) | 2007-01-26 | 2010-02-03 | 路易斯维尔大学研究基金会公司 | 用作疫苗的外来体组分的修饰 |
| US20080184391A1 (en) * | 2007-01-29 | 2008-07-31 | Kuppuswamy Subramaniam | Pathogen resistant transgenic plants, associated nucleic acids and techniques involving the same |
| CN101646769A (zh) | 2007-02-20 | 2010-02-10 | 孟山都技术公司 | 无脊椎动物微rna |
| ES2538217T3 (es) | 2007-03-21 | 2015-06-18 | Brookhaven Science Associates, Llc | Composiciones combinadas antisentido de horquilla y métodos para modular la expresión |
| EP2152903A2 (en) | 2007-04-26 | 2010-02-17 | Ludwig Institute for Cancer Research, Ltd. | Methods for diagnosing and treating astrocytomas |
| WO2008137115A1 (en) | 2007-05-03 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
| CA2728575A1 (en) * | 2007-06-29 | 2009-01-08 | Boston Biomedical, Inc. | Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells |
| US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| EP2185706B1 (en) | 2007-08-14 | 2017-09-27 | Commonwealth Scientific and Industrial Research Organisation | Improved gene silencing methods |
| KR101142209B1 (ko) | 2007-09-22 | 2012-05-04 | 재단법인서울대학교산학협력재단 | 섭취 ＲＮＡｉ를 이용한 꼬마선충에서 두 유전자의동시발현 억제방법 |
| US7968525B1 (en) | 2007-12-03 | 2011-06-28 | University Of Florida Research Foundation, Inc. | Use of RNA interference to validate new termiticide target sites and a method of termite control |
| BRPI0911332A2 (pt) | 2008-04-04 | 2019-09-24 | Calando Pharmaceuticals Inc | composições e uso de inibidores de epas1 |
| AU2009234229B2 (en) | 2008-04-10 | 2014-06-19 | Monsanto Technology Llc | Methods and compositions for root knot nematode control |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| US9289475B2 (en) | 2008-11-06 | 2016-03-22 | The Johns Hopkins University | Treatment of chronic inflammatory respiratory disorders |
| EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
| DK2379722T3 (da) | 2008-12-16 | 2017-01-02 | C-Lecta Gmbh | Ekspressionsvektor |
| WO2010074783A1 (en) | 2008-12-23 | 2010-07-01 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| BRPI1009271A8 (pt) | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | Molécula de ácido nucleico interferente curto de filamento duplo, composição farmacêutica, e, método para tratar um indivíduo humano que sofre de uma condição que é mediada pela ação, ou pela perda de ação, de bach1 |
| WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20110138223A (ko) | 2009-03-27 | 2011-12-26 | 머크 샤프 앤드 돔 코포레이션 | 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20100257634A1 (en) * | 2009-04-03 | 2010-10-07 | Venganza Inc. | Bioassay for gene silencing constructs |
| US8283332B2 (en) | 2009-04-17 | 2012-10-09 | University Of Louisville Research Foundation, Inc. | PFKFB4 inhibitors and methods of using the same |
| EP2258858A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
| US20120107243A1 (en) | 2009-07-14 | 2012-05-03 | Mayo Foundation For Medical Education And Research | Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier |
| IN2012DN00303A (is) | 2009-07-24 | 2015-05-08 | Univ California | |
| BR122018067960B8 (pt) | 2009-08-28 | 2022-12-06 | Du Pont | Polinucleotídeo isolado, cassete de expressão, método para controlar uma praga de plantas do tipo coleoptera e método para obtenção de uma planta |
| AU2010328295B2 (en) | 2009-12-07 | 2015-09-10 | The Johns Hopkins University | SR-BI as a predictor of human female infertility and responsiveness to treatment |
| KR101692063B1 (ko) | 2009-12-09 | 2017-01-03 | 닛토덴코 가부시키가이샤 | hsp47 발현의 조절 |
| US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
| ES2764999T3 (es) | 2009-12-10 | 2020-06-05 | Univ Columbia | Activadores de histona acetiltransferasa y usos de los mismos |
| JP5819848B2 (ja) | 2009-12-18 | 2015-11-24 | アローヘッド リサーチ コーポレイション | Ｈｓｆ１関連疾患を処置するための有機組成物 |
| CA2785492C (en) | 2009-12-23 | 2018-07-24 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2529033B1 (en) | 2010-01-26 | 2017-05-24 | National Jewish Health | Methods for risk prediction, diagnosis, prognosis of pulmonary disorders |
| JP2013519869A (ja) | 2010-02-10 | 2013-05-30 | ノバルティス アーゲー | 筋肉成長のための方法および化合物 |
| EP2571987B1 (en) | 2010-05-21 | 2017-03-01 | Peptimed, Inc. | Reagents for treating cancer |
| GB201009601D0 (en) | 2010-06-08 | 2010-07-21 | Devgen Private Ltd | Method for down-grading gene expression in fungi |
| WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| CN103140582A (zh) | 2010-08-24 | 2013-06-05 | 默沙东公司 | 含有内部非核酸间隔子的单链RNAi试剂 |
| WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
| CN108404115A (zh) | 2010-10-15 | 2018-08-17 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012061443A2 (en) | 2010-11-01 | 2012-05-10 | NanoOncology, Inc. | Compositions of a peptide-based system for cell-specific targeting |
| SI2635299T1 (sl) | 2010-11-02 | 2020-02-28 | The Trustees Of Columbia University In The City Of New York | Postopki za zdravljenje motenj izgube las |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CN103298939A (zh) | 2010-12-06 | 2013-09-11 | 夸克医药公司 | 包含位置修饰的双链寡核苷酸化合物 |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| CA2822621C (en) | 2010-12-22 | 2020-12-15 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase modulators and uses thereof |
| KR101937498B1 (ko) | 2011-03-03 | 2019-04-10 | 쿠아크 파마수티칼스 인코퍼레이티드 | 폐 질환 및 손상을 치료하기 위한 조성물 및 방법 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| CN103930165B (zh) | 2011-09-02 | 2018-05-25 | 纽约市哥伦比亚大学理事会 | 用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂 |
| US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
| CA2850032C (en) | 2011-10-14 | 2022-06-07 | Genentech, Inc. | Anti-htra1 antibodies and methods of use |
| PL3597644T3 (pl) | 2011-10-18 | 2022-01-17 | Dicerna Pharmaceuticals, Inc. | Aminowe lipidy kationowe i ich zastosowania |
| BR112014010769B1 (pt) | 2011-11-03 | 2021-08-03 | Quark Pharmaceuticals, Inc | Uso de um composto de rna de fita dupla para preparar um medicamento para tratar doença de ménière |
| CN104334191A (zh) | 2012-03-29 | 2015-02-04 | 纽约市哥伦比亚大学托管会 | 治疗毛发脱落疾病的方法 |
| BR112014025983A2 (pt) | 2012-04-20 | 2018-07-03 | Futuragene Israel Ltd | molécula de ácido ribonucleico, dsrna, vetor, célula hospedeira, tecido vegetal, ácido nucleico e métodos de produção de plantas e de inibição de infestação de pragas |
| BR112014026363A2 (pt) | 2012-04-23 | 2017-06-27 | Futuragene Israel Ltd | molécula de ácido ribonucleico, dsrna, vetor, célula hospedeira, tecido vegetal, ácido nucleico isolado, método de produção de planta resistente a pragas e método de inibição de infestação de pragas |
| EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| WO2014018554A1 (en) | 2012-07-23 | 2014-01-30 | La Jolla Institute For Allergy And Immunology | Ptprs and proteoglycans in autoimmune disease |
| WO2014053910A2 (en) | 2012-10-03 | 2014-04-10 | Futuragene Israel Ltd. | Gall wasp control agents |
| WO2014058915A2 (en) | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| US9920316B2 (en) | 2013-03-14 | 2018-03-20 | Pioneer Hi-Bred International, Inc. | Compositions and methods to control insect pests |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| EP2810952A1 (en) | 2013-06-03 | 2014-12-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel pest control methods |
| WO2015002969A1 (en) | 2013-07-03 | 2015-01-08 | City Of Hope | Anticancer combinations |
| EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
| CA2929574A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| WO2015098113A1 (ja) | 2013-12-27 | 2015-07-02 | 独立行政法人医薬基盤研究所 | 悪性腫瘍の治療薬 |
| US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| WO2016059187A1 (en) * | 2014-10-16 | 2016-04-21 | Universite De Strasbourg | Method of capturing and identifying novel rnas |
| CA2974716A1 (en) | 2014-11-12 | 2016-05-19 | Nmc, Inc. | Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same |
| EP3237452A4 (en) | 2014-12-23 | 2018-12-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| WO2016145005A1 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Rna nanoparticles for brain tumor treatment |
| WO2016145003A1 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Rna nanoparticle for treatment of gastric cancer |
| WO2016145008A2 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Mirna for treatment of breast cancer |
| US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| US10828381B2 (en) | 2015-04-17 | 2020-11-10 | University Of Kentucky Research Foundation | RNA nanoparticles and method of use thereof |
| US20180156807A1 (en) | 2015-04-29 | 2018-06-07 | New York University | Method for treating high-grade gliomas |
| WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| US10072065B2 (en) | 2015-08-24 | 2018-09-11 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier |
| EP3702470A3 (en) | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| WO2017059118A1 (en) | 2015-09-29 | 2017-04-06 | Duke University | Compositions and methods for identifying and treating dystonia disorders |
| SG10202001808VA (en) | 2015-10-30 | 2020-04-29 | Genentech Inc | Anti-htra1 antibodies and methods of use thereof |
| EP3386519B1 (en) | 2015-12-13 | 2021-03-24 | Nitto Denko Corporation | Sirna structures for high activity and reduced off target |
| US11072777B2 (en) | 2016-03-04 | 2021-07-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) |
| DK3429603T3 (da) | 2016-03-15 | 2022-03-14 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller |
| US10883108B2 (en) | 2016-03-31 | 2021-01-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
| WO2018057575A1 (en) | 2016-09-21 | 2018-03-29 | Alnylam Pharmaceuticals, Inc | Myostatin irna compositions and methods of use thereof |
| CN107858405B (zh) * | 2017-10-12 | 2021-09-24 | 华南农业大学 | 一种测定外源dsRNA对瓢虫毒性影响的方法 |
| WO2019199673A1 (en) | 2018-04-09 | 2019-10-17 | President And Fellows Of Harvard College | Modulating nuclear receptors and methods of using same |
| CN109183158B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母单杂交文库的构建方法 |
| CN109266677B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母双杂交文库的构建方法 |
| WO2020061381A1 (en) | 2018-09-19 | 2020-03-26 | La Jolla Institute For Immunology | Ptprs and proteoglycans in rheumatoid arthritis |
| WO2020102668A1 (en) | 2018-11-16 | 2020-05-22 | Nitto Denko Corporation | Rna interference delivery formulation and methods for malignant tumors |
| EP3907504A4 (en) * | 2019-01-04 | 2022-11-30 | Kyoto University | TEST PROCEDURE FOR ULCERATIVE COLITIS AND PRIMARY SCLEROTIC CHOLANGITIS |
| CN110229839B (zh) * | 2019-06-04 | 2021-06-08 | 中国农业大学 | 一种提升大肠杆菌dsRNA表达产率的方法 |
| CN110746497A (zh) * | 2019-11-18 | 2020-02-04 | 维塔恩(广州)医药有限公司 | 肺炎衣原体相关抗原短肽及其应用 |
| CN110804088A (zh) * | 2019-11-18 | 2020-02-18 | 维塔恩(广州)医药有限公司 | 巨细胞病毒相关抗原短肽及其应用 |
| EP3825408A1 (en) | 2019-11-19 | 2021-05-26 | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. | Methods of multi-species insect pest control |
| EP4077676A1 (en) | 2019-12-18 | 2022-10-26 | Novartis AG | Compositions and methods for the treatment of hemoglobinopathies |
| PE20230159A1 (es) | 2019-12-18 | 2023-02-01 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos |
| KR20220139886A (ko) | 2020-01-08 | 2022-10-17 | 리제너론 파아마슈티컬스, 인크. | 진행성 골화성 섬유이형성증의 치료 |
| US20210222128A1 (en) | 2020-01-22 | 2021-07-22 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
| US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| CN113638055B (zh) * | 2020-05-22 | 2023-07-07 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种制备双链rna测序文库的方法 |
| WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
| EP4359527A2 (en) | 2021-06-23 | 2024-05-01 | Novartis AG | Compositions and methods for the treatment of hemoglobinopathies |
| WO2023012165A1 (en) | 2021-08-02 | 2023-02-09 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
| CN113533007B (zh) * | 2021-08-06 | 2023-11-24 | 青岛瑞斯凯尔生物科技有限公司 | 一种抗体染色标记装置及其方法 |
| WO2024059618A2 (en) | 2022-09-13 | 2024-03-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed tgfbr shrnas |
| WO2024059824A2 (en) | 2022-09-16 | 2024-03-21 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US589801A (en) * | 1897-09-07 | woltereck | ||
| EP0477994B1 (en) | 1985-03-21 | 2001-06-13 | Johnston, Stephen, Ph.D. | Parasite-derived resistance |
| US6608241B1 (en) | 1985-10-29 | 2003-08-19 | Monsanto Technology Llc | Protection of plants against viral infection |
| IL81737A (en) | 1986-03-28 | 1992-11-15 | Calgene Inc | Regulation of gene expression in plant cells |
| US5017488A (en) * | 1986-04-01 | 1991-05-21 | University Of Medicine And Dentistry Of New Jersey | Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15 |
| US4970168A (en) * | 1989-01-27 | 1990-11-13 | Monsanto Company | Virus-resistant plants |
| EP0473576A4 (en) * | 1989-05-19 | 1993-03-10 | Hem Research, Inc. | Short therapeutic dsrna of defined structure |
| HUT57265A (en) | 1989-11-03 | 1991-11-28 | Zaadunie Bv | Process for producing plants of diminished infection-sensitivity |
| US5837848A (en) * | 1990-03-16 | 1998-11-17 | Zeneca Limited | Root-specific promoter |
| JPH05505727A (ja) * | 1990-03-30 | 1993-08-26 | プレジデント、アンド、フェローズ、オブ、ハーバード、カレッジ | トランスジェニック動物においてトランス遺伝子の発現をコントロールするバイナリー遺伝子系 |
| US5831011A (en) * | 1990-07-27 | 1998-11-03 | Mycogen Corporation | Bacillus thuringiensis genes encoding nematode-active toxins |
| US5459252A (en) * | 1991-01-31 | 1995-10-17 | North Carolina State University | Root specific gene promoter |
| JPH07506485A (ja) | 1992-03-20 | 1995-07-20 | マックス−プランク−ゲゼルシャフト ズール フェルデルング デル ヴィッセンシャフテン エー ファウ | 真菌応答性キメラ遺伝子 |
| DE4234131C2 (de) * | 1992-10-09 | 1995-08-24 | Max Planck Gesellschaft | Transgener pathogen-resistenter Organismus |
| CA2088379A1 (en) * | 1993-01-29 | 1994-07-30 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
| IL104830A (en) * | 1993-02-23 | 2001-01-28 | Yissum Res Dev Co | A chimeric plasmid containing a non-structural gene for the protease of the potato virus and its various uses |
| DE4317845A1 (de) | 1993-05-28 | 1994-12-01 | Bayer Ag | Desoxyribonukleinsäuren |
| MX9606362A (es) * | 1994-06-15 | 1997-03-29 | Univ Columbia | Metodo para identificar genes supresores de tumor. |
| US5691140A (en) * | 1995-05-18 | 1997-11-25 | New England Biolabs, Inc. | Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions |
| GB9510944D0 (en) * | 1995-05-31 | 1995-07-26 | Bogaert Thierry | Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour |
| DE69610310T2 (de) * | 1995-06-02 | 2001-03-15 | M & E Biotech As Horsholm | Verfahren zur identifikation von biologisch aktiven peptiden und nukleinsäuren |
| US5679551A (en) * | 1995-10-31 | 1997-10-21 | Board Of Regents, The University Of Texas System | Unique double-stranded RNAS associated with the Trichomonas vaginalis virus |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
| KR20000029896A (ko) * | 1996-08-09 | 2000-05-25 | 자뷰 마크 | 선충및/또는진딧물에대한내성유전자 |
| US6294712B1 (en) * | 1996-09-18 | 2001-09-25 | Christian Jung | Nematode-resistant gene |
| WO1998014536A1 (fr) | 1996-10-03 | 1998-04-09 | Hajime Kato | .procede de reformage d'hydrocarbures a l'aide de vapeur |
| ES2160374T3 (es) | 1996-12-18 | 2001-11-01 | Exxonmobil Chem Patents Inc | Mezclas de polimeros compatibilizadas, formadas utilizando un agente multifuncional. |
| GB9703146D0 (en) | 1997-02-14 | 1997-04-02 | Innes John Centre Innov Ltd | Methods and means for gene silencing in transgenic plants |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| EP3214177A3 (en) * | 1998-04-08 | 2017-11-22 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
| AR020078A1 (es) * | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| GB9814536D0 (en) | 1998-07-03 | 1998-09-02 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AUPR621501A0 (en) | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
| AU2006292362B2 (en) | 2005-09-16 | 2013-02-14 | Monsanto Technology Llc | Methods for genetic control of insect infestations in plants and compositions thereof |
-
1998
- 1998-12-09 GB GBGB9827152.1A patent/GB9827152D0/en not_active Ceased
-
1999
- 1999-07-02 CA CA2332619A patent/CA2332619C/en not_active Expired - Fee Related
- 1999-07-02 CZ CZ2012-309A patent/CZ304897B6/cs not_active IP Right Cessation
- 1999-07-02 BR BR9911802-5A patent/BR9911802A/pt active Search and Examination
- 1999-07-02 PT PT01129274T patent/PT1197567E/pt unknown
- 1999-07-02 PT PT04011161T patent/PT1484415E/pt unknown
- 1999-07-02 DE DE69940219T patent/DE69940219D1/de not_active Expired - Lifetime
- 1999-07-02 CN CNA2006100944808A patent/CN1900319A/zh active Pending
- 1999-07-02 EP EP99932836A patent/EP1093526A2/en not_active Withdrawn
- 1999-07-02 CN CN200510052742XA patent/CN1657620A/zh active Pending
- 1999-07-02 GB GB0020485A patent/GB2349885B/en not_active Expired - Fee Related
- 1999-07-02 GB GB0118514A patent/GB2362885B/en not_active Expired - Fee Related
- 1999-07-02 ES ES04011161T patent/ES2327334T3/es not_active Expired - Lifetime
- 1999-07-02 EP EP08022353A patent/EP2045336A3/en not_active Withdrawn
- 1999-07-02 DE DE29924299U patent/DE29924299U1/de not_active Expired - Lifetime
- 1999-07-02 EP EP04011161A patent/EP1484415B1/en not_active Revoked
- 1999-07-02 DE DE29924298U patent/DE29924298U1/de not_active Expired - Lifetime
- 1999-07-02 PL PL390495A patent/PL216779B1/pl unknown
- 1999-07-02 KR KR20047010184A patent/KR20040066200A/ko active Search and Examination
- 1999-07-02 JP JP2000558236A patent/JP4353639B2/ja not_active Expired - Fee Related
- 1999-07-02 CN CNB998101966A patent/CN1198938C/zh not_active Expired - Fee Related
- 1999-07-02 IL IL14046799A patent/IL140467A0/xx active IP Right Grant
- 1999-07-02 DE DE69940984T patent/DE69940984D1/de not_active Expired - Lifetime
- 1999-07-02 GB GB0206600A patent/GB2370275B/en not_active Expired - Fee Related
- 1999-07-02 AT AT01129274T patent/ATE419383T1/de active
- 1999-07-02 HU HU0103571A patent/HU230602B1/hu not_active IP Right Cessation
- 1999-07-02 KR KR1020077005038A patent/KR20070041607A/ko active Search and Examination
- 1999-07-02 DE DE1093526T patent/DE1093526T1/de active Pending
- 1999-07-02 DK DK04011161T patent/DK1484415T3/da active
- 1999-07-02 PL PL384205A patent/PL213379B1/pl unknown
- 1999-07-02 AU AU49079/99A patent/AU769223B2/en not_active Ceased
- 1999-07-02 NZ NZ509182A patent/NZ509182A/en not_active IP Right Cessation
- 1999-07-02 DK DK01129274.5T patent/DK1197567T4/en active
- 1999-07-02 AT AT04011161T patent/ATE433500T1/de active
- 1999-07-02 PL PL347978A patent/PL201425B1/pl unknown
- 1999-07-02 CZ CZ20010014A patent/CZ303494B6/cs not_active IP Right Cessation
- 1999-07-02 KR KR1020017000068A patent/KR100563295B1/ko not_active IP Right Cessation
- 1999-07-02 CA CA2789083A patent/CA2789083C/en not_active Expired - Fee Related
- 1999-07-02 ES ES01129274.5T patent/ES2320527T5/es not_active Expired - Lifetime
- 1999-07-02 RU RU2000133315/13A patent/RU2240349C2/ru not_active IP Right Cessation
- 1999-07-02 MX MXPA00012955 patent/MX234065B/es not_active IP Right Cessation
- 1999-07-02 KR KR1020067011420A patent/KR20060071438A/ko active Search and Examination
- 1999-07-02 WO PCT/EP1999/004718 patent/WO2000001846A2/en active Application Filing
- 1999-07-02 EP EP10182431A patent/EP2374901A1/en not_active Withdrawn
- 1999-07-02 EP EP01129274.5A patent/EP1197567B2/en not_active Expired - Lifetime
-
2000
- 2000-12-06 HK HK00107819A patent/HK1029142A1/xx not_active IP Right Cessation
- 2000-12-19 ZA ZA200007653A patent/ZA200007653B/en unknown
- 2000-12-21 IL IL140467A patent/IL140467A/en not_active IP Right Cessation
-
2001
- 2001-01-02 IN IN6DE2001 patent/IN2001DE00006A/en unknown
- 2001-01-02 IS IS5802A patent/IS2816B/is unknown
- 2001-01-02 NO NO20010019A patent/NO327729B1/no not_active IP Right Cessation
-
2002
- 2002-01-25 US US10/057,108 patent/US20030061626A1/en not_active Abandoned
-
2003
- 2003-12-17 US US10/738,886 patent/US20040133943A1/en not_active Abandoned
-
2004
- 2004-04-16 US US10/826,522 patent/US8114980B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 IN IN3568DE2006 patent/IN2006DE03568A/en unknown
-
2007
- 2007-03-06 IL IL181727A patent/IL181727A/en not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001591A patent/JP2009112311A/ja active Pending
- 2009-03-23 CY CY20091100345T patent/CY1108920T1/el unknown
- 2009-08-31 CY CY20091100907T patent/CY1109324T1/el unknown
-
2013
- 2013-09-09 JP JP2013186110A patent/JP5847776B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1197567B1 (en) | Characterisation of gene function using double stranded RNA inhibition | |
| JP6665088B2 (ja) | 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物 | |
| Lozano et al. | Efficient gene targeting and removal of foreign DNA by homologous recombination in the picoeukaryote Ostreococcus | |
| CN107142247A (zh) | 可诱导的CRISPRon或CRISPRi小鼠胚胎干细胞及其应用 | |
| US9085767B2 (en) | Enhancer-containing gene trap vectors for random and targeted gene trapping | |
| US7005423B1 (en) | Characterization of gene function using double stranded RNA inhibition | |
| AU2004200852B2 (en) | Characterisation of gene function using double stranded RNA inhibition | |
| El Mouridi et al. | Targeted and Random Transposon-Assisted Single-Copy Transgene Insertion in C. elegans | |
| Deka | Gene Cloning | |
| McEachern | Inter-kingdom epigenetics: characterization of maize b1 tandem repeat-mediated silencing in Drosophila melanogaster | |
| Gu | Characterization of transcription termination by RNA polymerase II in the mouse histone H2a-614 gene |